Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease

Chronic Kidney Disease Clinical Trial

Official title:

Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03581071
• Other study ID #: TS143-01-02
• Secondary ID: JapicCTI-163383
• Status: Completed
• Phase: Phase 1
• Start date: October 6, 2016
• Est. completion date: July 6, 2017

Study information

• Verified date: July 2018
• Source: Taisho Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety, pharmacokinetics, and pharmacodynamics in nondialysis (ND) and hemodialysis (HD) subjects with Chronic Kidney Disease (CKD) who receive a single administration of TS-143.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: July 6, 2017
• Est. primary completion date: July 6, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 74 Years

Eligibility

Inclusion Criteria:

• Serum concentration of erythropoietin (EPO): <50 mIU/mL at screening test 1, 2, or 3

• Transferrin saturation = 20% or ferritin = 100 ng/mL at screening test 1

• Subjects meeting any of the following criteria

1. Subjects who has not used erythropoiesis-stimulating agent (ESA) = eight weeks from screening test 1

2. Subjects who has used ESA, other than epoetin beta pegol, = four weeks from screening test 1 and has met all of the following criteria A) to C).

A)The total ESA dosage for each week could be changed within a range of 50%, compared to the total ESA dosage for one week before screening test 1, for four weeks before screening test 1 B)Acceptable to discontinue ESA the day following screening test 1 to Follow-up 2 C)The fluctuating range of Hb concentration between screening tests 1 and 2 is within ±0.5 g/dL per week (the same criteria applied between screening test 2 and 3)

• Subjects who receive an explanation about the study before participating in the study and can understand the contents and are willing and able to provide written consent.

<Criteria for ND subjects>

• CKD subjects who never received dialysis and do not need to receive dialysis during the study period.

• Subjects with an Hb concentration at screening test 1 (ESA present at screening test 2) = 10.0 g/dL to < 13.0 g/dL.

• Subjects with an eGFR at screening test 1 = 15 mL/min/1.73m^2 to < 45 mL/min/1.73m^2.

<Criteria for HD subjects>

• Subjects who received hemodialysis (including diafiltration) three times per week = 12 weeks from acquisition consent.

• Subjects with an Hb concentration at screening test 1 (ESA present at screening test 2) = 10.0 g/dL to < 12.0 g/dL.

Exclusion Criteria:

• Subjects with anemia other than that caused by CKD.

• Subjects who have severe infection, systemic hematopathy (e.g. myelodysplastic syndrome, hemoglobinopathy), peptic ulcer or clear hemorrhagic lesion such as gastrointestinal hemorrhage

• Subjects with immune disorder with severe inflammation

• Subjects with uncontrolled secondary hyperparathyroidism

• Subjects who already had or will have a kidney transplantation

• Subjects who have a complication which requires treatment such as proliferative retinopathy, macular edema, or macular degeneration. Or, subjects who had a complication which required treatment such as proliferative retinopathy, macular edema, or macular degeneration within 12 months from screening test 1

• Subjects with congestive heart failure

• Subjects with a medical history of thrombotic disease in the six months from screening test 1

• Subjects with uncontrolled blood pressure; SBP > 170 mmHg or DBP > 100 mmHg at screening test 1 (ESA present, screening tests 1 and 2), (HD subject, evaluated before dialysis)

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• TS-143

Locations

Country	Name	City	State
Japan	Taisho Pharmaceutical Co., Ltd selected site	Multiple Locations

Sponsors (1)

Lead Sponsor	Collaborator
Taisho Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Shinfuku A, Shimazaki T, Fujiwara M, Sato F, Watase H, Numazaki T, Kawakita Y, Mutoh M, Yamasaki H, Takayama N, Kato S, Sugimoto T, Maruyama J. Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and He — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events	To evaluate the safety of TS-143 given single administration in CKD patients by incidence of adverse events which include abnormal electrocardiograms, vital signs, and clinical laboratory parameters.	8 days
Primary	Plasma concentrations of unchanged form (ng/mL)	The descriptive statistics (e.g., number of subjects, arithmetic mean, standard deviation) were calculated by dose group and evaluation timing.	7 days
Primary	Urinary excretions of unchanged form (ng/mL)	The descriptive statistics (e.g., number of subjects, arithmetic mean, standard deviation) for the total urinary excretion (amount and fraction) were summarized by dose group.	24 hours
Primary	Serum EPO concentration		4 days
Primary	Reticulocyte count		7 days
Primary	Plasma vascular endothelial growth factor (VEGF) concentration		4 days